Wang Xinwei, Zeng Yun, Zhang Junling, Huang Mengli, Yin Bijian
Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Medical Department, 3D Medicines Inc., Shanghai, China.
Front Oncol. 2022 Jul 8;12:940263. doi: 10.3389/fonc.2022.940263. eCollection 2022.
Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatment regimens to improve patient outcomes. A 65-year-old man with mGC was HER-2 positive. Standard trastuzumab, combined with chemotherapy, was given in the first-line therapy and progression-free survival (PFS) was 8 months. Second-line treatment with pyrotinib in combination with trastuzumab and chemotherapy yielded a PFS of 20 months, in sharp contrast to a median survival of 2.9-6.2 months for a majority of advanced GC patients. This case provides a meaningful reference for the second-line treatment of mGC patients with HER-2 positive. This case also provides valuable information on the response to pyrotinib plus trastuzumab of patients with brain metastases and a better understanding of dual target combination therapy applications in the future.
胃癌（GC）是一种具有大分子表型异质性且预后较差的疾病，尤其是转移性胃癌（mGC）。化疗是二线治疗的首选。然而，二线化疗的益处有限，因此迫切需要新的治疗方案来改善患者预后。一名65岁的mGC男性患者HER-2呈阳性。一线治疗给予标准曲妥珠单抗联合化疗，无进展生存期（PFS）为8个月。二线使用吡咯替尼联合曲妥珠单抗和化疗，PFS为20个月，这与大多数晚期GC患者2.9 - 6.2个月的中位生存期形成鲜明对比。该病例为HER-2阳性的mGC患者的二线治疗提供了有意义的参考。该病例还提供了关于脑转移患者对吡咯替尼加曲妥珠单抗反应的有价值信息，以及对未来双靶点联合治疗应用的更好理解。
